Penn Pharma's equipment addition meets growing need for continuous dry granulation and for handling of highly potent drugs.
Pharmaceutical manufacturer, Penn Pharma, a PCI company, has invested in a contained Gerteis Mini-Pactor for roller compaction of oral solid-dosage drugs containing potent APIs at its Tredegar site in South Wales, the company announced on Mar. 11, 2015.
Roller compaction provides a granulation method for materials that are heat and moisture sensitive, and avoids the use of liquid and high temperatures associated with wet granulation and subsequent drying methods. The Gerteis Mini-Pactor design enhances powder flow and offers effective containment using skan isolator technology and integrated cleaning systems. The process is easily scalable.
"We have recognized and responded to a growing need within the industry for continuous granulation methods by developing our dry granulation capabilities," said Mark Dean-Netscher, vice-president of International Operations at Penn Pharma, in the press release. "This roller compactor can be used from 1-kg development scale up to 100 kg/h at production scale, without the need for additional scale-up work. This will significantly reduce our clients' costs and allow products to be developed and delivered to market far quicker."
Source: Penn Pharma
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Entering New Domains for 3D Printing of Drug Products
April 6th 20253D printing of personalized medications is currently possible under existing compounding regulations, offering enhanced process control through automation. But new legislation coming in 2025 will allow 3D printing as part of a distributed manufacturing framework.